Guerbet S.A.

Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
  • TickerGBT
  • ISINFR0000032526
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Pierre Vaurice

Guerbet. Initiation de couverture

​Un nouveau leader en puissance dans l’imagerie médicaleGuerbet est une ETI française qui fait partie du top4 des acteurs présents dans l’industrie des agents de contraste pour l’imagerie médicale. Pure-player dès son origine avec un portefeuille ancré dans les rayons X (376M€) mais aussi dans l’IRM (247M€) avec son produit-phare Dotarem, le groupe dispose d’un portefeuille de produits incontournables et différenciants permettant de consolider son leadership. 

Pierre Vaurice

Guerbet : leader in the making

​Guerbet is a French mid-cap that is among the top four players in the industry of contrast media for medical imaging. A pure player right from the beginning, with a portfolio firmly rooted in X-rays (€376 million in 2016, 48.4% of revenue) and also in MRI (€247 million in 2016, 31.8% of revenue) with its flagship product Dotarem, the group has a portfolio of key and differentiating products, enabling its leadership to be consolidated. The current integration of CMDS gives Guerbet a critical size and a global footprint that will contribute to asserting its leadership over the coming years.

Pierre Vaurice

Guerbet. Initiation de couverture

​Un nouveau leader en puissance dans l’imagerie médicaleGuerbet est une ETI française qui fait partie du top4 des acteurs présents dans l’industrie des agents de contraste pour l’imagerie médicale. Pure-player dès son origine avec un portefeuille ancré dans les rayons X (376M€) mais aussi dans l’IRM (247M€) avec son produit-phare Dotarem, le groupe dispose d’un portefeuille de produits incontournables et différenciants permettant de consolider son leadership. 

Pierre Vaurice

Guerbet : leader in the making

​Guerbet is a French mid-cap that is among the top four players in the industry of contrast media for medical imaging. A pure player right from the beginning, with a portfolio firmly rooted in X-rays (€376 million in 2016, 48.4% of revenue) and also in MRI (€247 million in 2016, 31.8% of revenue) with its flagship product Dotarem, the group has a portfolio of key and differentiating products, enabling its leadership to be consolidated. The current integration of CMDS gives Guerbet a critical size and a global footprint that will contribute to asserting its leadership over the coming years.

Pierre Vaurice

Guerbet. Feedback déjeuner investisseurs

​Nous revenons ce matin sur le déjeuner investisseurs organisé hier avec Guerbet. Ce déjeuner était l'opportunité de faire un point sur les deux "hot topics" du moment dans le segment IRM: l'arrivée de General Electric (GE) avec un générique de Dotarem (nom commercial Clariscan) et l'ouverture fort probable du marché européen avec le retrait des produits linéaires.

Pierre Vaurice

Guerbet. Still confident

​We return this morning to the investor lunch organised yesterday with Guerbet. This lunch was an opportunity to check progress on the two current "hot topics" in the MRI segment: the generic version of Dotarem (trade name Clariscan) from General Electric (GE) and the very likely opening of the European market with the withdrawal of linear products.

Pierre Vaurice

Guerbet. Confirmation du retrait d'Hexabrix/Optimark

​Guerbet confirme ce matin le plan de rationalisation de 2 produits de contraste: Hexabrix (rayons X) et Optimark (IRM).

1 director sold

A director at Guerbet sold 1,000 shares at 47.200EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Benoit Valleaux
  • Bruno Hareng
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fehmi Ben Naamane
  • Hana Maalej
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Matthias Desmarais
  • Nicolas David
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby
  • Rémi Adam, CFA
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - Date1

...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Benoit Valleaux
  • Bruno Hareng
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Fehmi Ben Naamane
  • Hana Maalej
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Laurence Hofmann
  • Matthias Desmarais
  • Nicolas David
  • Olivier Lebrun
  • Oussema Denguir
  • Pierre Corby
  • Rémi Adam, CFA
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - Date1

...

Christophe-Raphaël Ganet ...
  • Michael Foundoukidis
  • Sylvain Goyon, CFA
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/08/2018

La poursuite de la normalisation monétaire de la FED, l’imminence quasi-certaine de celle de la BCE, devraient, dans un contexte d’interrogations sur la position cyclique « réelle » de part et d’autre de l’Atlantique, placer l’évolution des taux en tête des préoccupations des investisseurs. Nous avons donc cherché à déterminer, via le calcul des corrélations hebdomadaires sur 6 mois, les secteurs et valeurs européens les plus sensibles à cette future thématique. Pour une hausse des ta...

Christophe-Raphaël Ganet ...
  • Michael Foundoukidis
  • Sylvain Goyon, CFA
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 08/28/2018

The ongoing monetary normalisation by the Fed and the imminent prospect of a similar move by the ECB, amid question marks over the real cyclical position on either side of the Atlantic, will likely put rate trends at the top of investors’ list of concerns. We have thus sought to determine the European sectors and stocks with the most exposure to this theme going forward, using weekly 6-month correlations. For a rate increase, the analysis gives a long position on banks, insurance, oil...

Alex Koagne ...
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Harold De Decker
  • Jean Sassus
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 26/09/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GUERBET sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of GUERBET (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date August 30, 2019, the closing price was EUR 48.85 and its target price was estimated at EUR 41.69.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Charles Pinel

Guerbet SA - Assemblée Générale des actionnaires du 24 mai 2019

Le conseil d'administration ne comprendra plus de dirigeant car le mandat d'administrateur du Directeur Général qui arrive à échéance n'est pas renouvelé. Il comprendra donc 10 membres contre 11 précédemment mais il est toujours composé d'une majorité de membres non libres de conflits d'intérêts potentiels, ce qui ne permet pas d'approuver le renouvellement d'un membre de la famille Guerbet, d'autant plus que cette famille est en sur-représentation avec 60% des sièges du conseil pour 53% du capital (résolution 13). Comme chaque année, les politiques de rémunération des dirigeants mandataires ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch